ABVC BioPharma, Inc.
ABVC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.22 | -0.03 | 0.01 | -0.04 |
| FCF Yield | -0.19% | -2.32% | -3.40% | -6.34% |
| EV / EBITDA | -61.54 | -18.96 | -29.46 | 32.35 |
| Quality | ||||
| ROIC | -7.35% | -20.86% | -6.80% | -10.52% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 100.05% |
| Cash Conversion Ratio | 0.11 | 0.40 | 0.57 | -2.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.58% | -20.05% | -22.03% | -19.30% |
| Free Cash Flow Growth | 85.10% | -65.64% | -9.36% | -387.44% |
| Safety | ||||
| Net Debt / EBITDA | -1.03 | -0.57 | -3.32 | 7.08 |
| Interest Coverage | 37.74 | -17.73 | -3.11 | 0.99 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 7.05 | 9.94 | 0.00 |
| Cash Conversion Cycle | 0.00 | 12.76 | 9.05 | 52,903.10 |